Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 5,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 70
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 41 more

Conditions: Malaria
Interventions: PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline; Biological · Other
Lead sponsor: Sanaria Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Influenza, COVID-19
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Acute Bacterial Skin and Skin Structure Infections
Interventions: NXL103, Linezolid; Drug
Lead sponsor: Novexel Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Chula Vista, California • Fountain Valley, California • La Mesa, California + 7 more

Conditions: Infections, Gram-positive Bacterial
Interventions: Telavancin, vancomycin or antistaphylococcal penicillin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: National City, California

Conditions: Diabetic Foot Ulcer
Interventions: NOX1416 and SOC, SOC (Standard of care); Drug · Procedure
Lead sponsor: NOxy Health Products, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Coral Gables, Florida + 9 more

Conditions: Cytomegalovirus Infections
Interventions: ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 1 Month
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sepsis, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Infection
Interventions: Drotrecogin Alfa (activated); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 5
States / cities: Denver, Colorado • Iowa City, Iowa • Manhassaet, New York + 2 more

Conditions: Latent Tuberculosis, HIV Infections
Interventions: T-Spot.TB test; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Sexually Transmitted Diseases, Reproductive Behavior
Interventions: SexHealth; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 14 Years to 19 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 14
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 10 more

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: La Jolla, California • Pasadena, California • Tampa, Florida + 7 more

Conditions: Acute Respiratory Infections (ARIs)
Interventions: FebriDx; Device
Lead sponsor: Lumos Diagnostics; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Colton, California • Clearwater, Florida • Lutz, Florida + 7 more

Conditions: Pressure Ulcers
Interventions: DermaTherapy® Linen and underpads.; Device
Lead sponsor: Precision Fabrics Group, Inc.; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cystic Fibrosis
Interventions: azithromycin, placebo, Tobramycin solution for inhalation; Drug
Lead sponsor: Bonnie Ramsey; Other
Eligibility: 6 Months to 18 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 45
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 18 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 33
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 21 more

Conditions: Influenza
Interventions: Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 3,027 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Sacramento, California • Boca Raton, Florida • Wichita, Kansas + 10 more

Conditions: Dementia Caregivers
Interventions: LST-LC Education; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Bacterial Infections
Interventions: Debio 1450 IV, Debio 1450 Oral, Linezolid, Debio 1450 Oral Placebo, Linezolid Placebo, Vancomycin IV; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Anaheim, California • Buena Park, California • Chula Vista, California + 17 more

Conditions: Influenza
Interventions: Peramivir; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Brooksville, Florida • Lakeland, Florida • Miami, Florida + 12 more

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2004
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Hepatitis C, Chronic
Interventions: Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV-1-infection, Metabolic Syndrome, Cardiovascular Diseases, Weight Gain, Renal Function Abnormal, Hyperglycemia
Interventions: Tenofovir Alafenamide; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma, Allergy
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 1 Minute to 2 Minutes
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

Respiratory Virus Sampling and Repository

Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers

A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?

Enhanced SexHealth Intervention to Improve Adolescent Outcomes

The Effects of Illnesses on HIV Levels in the Body

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

FebriDx® Pediatric Validation Study

Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

Juntos/Together Program to Build Confidence for Complex Care Tasks Among Latino Family Caregivers

Study of Debio 1450 for Bacterial Skin Infections

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

Childhood Origins of Asthma (COAST)